PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced that the Company has entered an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly MEDI2452), a Phase 1-ready reversal agent for ticagrelor.
{iframe}http://markets.businessinsider.com/news/stocks/PhaseBio-Enters-Worldwide-License-Agreement-with-MedImmune-for-a-Reversal-Agent-for-Ticagrelor-1009785814{/iframe}